Our results suggest that the immunosuppressant effects of glimepiride were mediated by the reduced expression of CD14, a molecule that acts as a receptor for LPS and neurotoxic peptides associated with prion, Alzheimer’s disease and Parkinson’s disease. This evidence concerns the gene CD14 and Parkinson disease.